White House staff are reviewing a proposal that may require pharmaceutical companies to be more transparent about their pricing, a key piece of President Donald Trump’s plan to lower drug costs. The Office of Management and Budget (OMB) has received a proposed regulation by the Department of Health and Human Services (HHS) that deals with drug-pricing transparency in the U.S. Medicare and Medicaid systems. OMB typically reviews regulations before they’re made public. The Senate, meanwhile, is debating a spending bill for HHS. Senators Chuck Grassley, an Iowa Republican, and Dick Durbin, an Illinois Democrat, have proposed an amendment that would fund requiring drugmakers to post prices on direct-to-consumer advertising. The senators say the amendment would bring more transparency. (Anna Edney, Bloomberg News)
